We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





Noul Demonstrates AI-Driven On-Site Diagnostics Platform at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The miLab AI-based electro-dynamic blood diagnostic platform (Photo courtesy of Noul)
Image: The miLab AI-based electro-dynamic blood diagnostic platform (Photo courtesy of Noul)

Noul Co., Ltd. (Gyeonggi-do, Korea) is demonstrating the world’s first integrated device featuring fully-automated sample preparation and AI-based diagnosis at the 2022 edition of MEDICA being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Noul is demonstrating miLab, which is the world’s first all-in-one, fully-automated device which can process sample preparation and AI diagnostic in one workflow. miLab integrates cutting edge technologies from computer vision AI, bio, hardware and software engineering. From automated sample preparation to imaging and AI analysis, the miLab platform combines the gold standard in blood diagnostics into a fully automated benchtop platform. Combined with embedded AI and the company’s patented Next Generation Staining and Immunostaining (NGSI) cartridges, miLab provides an accurate analysis in 20 minutes using just 5 uL of blood. NGSI, the patented solid-based staining technology can replace the current liquid-based sample preparation methods and possess the potential to expand applicabilities to other diagnostic areas. NGSI technology eliminates the liquid usage in the sample staining process and can complete it in only a few minutes using a single step stamping method.

miLab provides superior accuracy compared to the competing technologies by combining multi-focus imaging and the state-of-the-art AI algorithm. The company’s AI can perfectly replicate the diagnosis of an expert microscopist without the errors and deviations. miLab’s AI algorithm analyzes multi-layered digital images of smeared blood cells to achieve 99%+ specificity in order to classify and detect parasite-infected cells. Among Noul’s offerings is the miLab Malaria which detects different stages of Plasmodium Falciparum and Plasmodium Vivax species and the miLab BCM which provides a morphology-based white blood cell (WBC) differential and cell count estimations, allowing decentralized health facilities to perform a WBC differential count and CBC estimation.

Related Links:
Noul Co., Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.